The revenue stands at ₹304.17 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 17.42 per cent from ₹368.33 crore. This corresponds to a year-on-year *(YoY) growth of 15.57 per cent.
Operating Profit stands at ₹14.00 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 53.24 per cent from ₹29.94 crore. This corresponds to a year-on-year *(YoY) growth of 348.23 per cent.
PBDT stands at ₹14.24 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 61.24 per cent from ₹36.74 crore. This corresponds to a year-on-year *(YoY) growth of 194.21 per cent.
Profit Before Tax stands at ₹3.29 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 87.27 per cent from ₹25.84 crore. This corresponds to a year-on-year *(YoY) growth of 157.82 per cent.
Net Profit stands at ₹3.22 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 87.54 per cent from ₹25.84 crore. This represents a 156.59 per cent year-on-year *(YoY) growth for the same year.
in ₹ cr
in ₹ cr
in ₹ cr
in ₹ cr
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Orchid Pharma | -3.67% | 3.40% | -7.84% | 6.73% | 81.93% | 37.53% |
| SPARC | -1.22% | -5.60% | -3.95% | -12.91% | 59.34% | 35.76% |
| Morepen Labs. | -0.78% | -3.71% | 55.34% | 127.77% | 183.57% | 111.93% |
| IOL Chemicals | -4.02% | -4.81% | 28.15% | 51.06% | 186.89% | 75.33% |
| Novartis India | -3.34% | 42.94% | 46.99% | 79.78% | 144.69% | 155.31% |
| FDC | -1.79% | -0.60% | -3.87% | -12.25% | -7.25% | -26.56% |
| Guj. Themis Bio. | -2.61% | -2.60% | 18.61% | 7.96% | 40.77% | 10.66% |
Chairman(Non Exe)&Dir(Non-Ind) : R G Agarwal
Executive Director & MD : Manish Dhanuka
E D & Wholetime Director : Mridul Dhanuka
Non-Exec & Non-Independent Dir : Arjun Dhanuka
Independent Non Exe. Director : Dharam Vir
Independent Non Exe. Director : Manoj Goyal
Independent Non Exe. Director : Tanu Singla
Independent Non Exe. Director : Shubha Singh
Company Sec. & Compli. Officer : Kapil Dayya